28-Aug-2026
PRNewswire (Thu, 27-Aug 5:28 PM ET)
Replimune Group Lawsuit: Company Asks Court to Dismiss Securities Case Over RP1 FDA Approval Process
TipRanks (Thu, 27-Aug 1:35 PM ET)
Globe Newswire (Thu, 27-Aug 11:10 AM ET)
PRNewswire (Thu, 27-Aug 10:07 AM ET)
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law
PRNewswire (Thu, 27-Aug 4:17 AM ET)
PRNewswire (Thu, 27-Aug 4:15 AM ET)
PRNewswire (Wed, 26-Aug 10:09 AM ET)
PRNewswire (Tue, 25-Aug 5:00 PM ET)
Globe Newswire (Tue, 25-Aug 4:07 PM ET)
Globe Newswire (Mon, 24-Aug 10:26 AM ET)
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
Replimune Group trades on the NASDAQ stock market under the symbol REPL.
As of August 28, 2026, REPL stock price declined to $15.50 with 2,281,526 million shares trading.
REPL has a beta of -1.21, meaning it tends to be less sensitive to market movements. REPL has a correlation of 0.01 to the broad based SPY ETF.
REPL has a market cap of $1.46 billion. This is considered a Small Cap stock.
Last quarter Replimune Group reported $0 in Revenue and -$.72 earnings per share. This fell short of revenue expectation by $-8 million and exceeded earnings estimates by $.04.
In the last 3 years, REPL traded as high as $21.32 and as low as $1.50.
The top ETF exchange traded funds that REPL belongs to (by Net Assets): XBI, IWM, VTI, IWN, VXF.
REPL has outperformed the market in the last year with a price return of +188.1% while the SPY ETF gained +19.7%. REPL has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +231.2% and +3.5%, respectively, while the SPY returned +2.2% and -0.9%, respectively.
REPL support price is $14.34 and resistance is $16.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that REPL shares will trade within this expected range on the day.